Skip to Content
Merck
  • Protective effect of inducible aldo-keto reductases on 4-hydroxynonenal- induced hepatotoxicity.

Protective effect of inducible aldo-keto reductases on 4-hydroxynonenal- induced hepatotoxicity.

Chemico-biological interactions (2019-03-09)
Dan Li, Zhuoliang Gu, Jingdong Zhang, Shuren Ma
ABSTRACT

4-Hydroxynonenal (HNE), an end-product of lipid peroxidation generated in response to oxidative stress, has been implicated in the pathophysiology of chronic liver diseases. HNE is very reactive that forms Michael adducts with nucleophilic sites in DNA, lipids and proteins. At high concentrations, HNE causes rapid cell death associated with depletion of sulfhydryl groups and inhibition of key metabolic enzymes. At low concentrations, HNE stimulates expression of genes that are part of an adaptive response. In this study, we show that sub-lethal concentrations of HNE induce mRNA expression levels of heme oxygenase-1 (HO-1) (2.5-fold), NADPH:quinone oxidoreductase (NQO1) (4.5-fold), AKR1C3 (2-fold) and AKR7A2 (3-fold) enzymes. Protein expression levels of AKR1C and AKR7A2 are induced by 2- and 1.5-fold following exposure to HNE. The role of AKR1C3 and AKR7A2 in protecting HepG2 cells against HNE toxicity was investigated through using RNAi. Results show that AKR7A2, but not AKR1C3 contributes to the protection against HNE toxicity in HepG2 cells. Moreover, transcriptional factor nuclear factor erythroid 2 p45-related factor 2 (Nrf2) is activated by HNE through translocation to the nucleus. Overexpressing AKR7A2 could rescue the effect of knocking down Nrf2 on HNE-induced cytotoxicity. Furthermore, a natural compound 7-hydroxycoumain, an AKR7A2 inducer, shows hepatoprotection against HNE via AKR7A2 induction. Hence, the inducible AKR7A2 has provided a new therapeutic target to treat chronic liver disease.